High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy

Table 2 Tumor response by treatment (including tumor characteristics), n (%)

	Total number of patients (n1 = 27)	TACE only (n = 14)	Combination of TACE and SBRT (n = 9)	SBRT only (n = 4)	P value
Complete response	9 (33.3)	0 (0)	8 (88.89)	1 (25)	< 0.001
Number of tumor lesions					0.517
1	20 (74)	9 (64)	8 (89)	3 (75)
2	7 (26)	5 (36)	1 (11)	1 (25)
Mean tumor size2	29.3 ± 9.46	29.50 ± 7.63	27.67 ± 9.54	26.67 ± 14.50	0.389
BCLC4
0	1 (4)	0 (0)	0 (0)	1 (25)
A	26 (96)	14 (100)	9 (100)	3 (75)
Median AFP3,5	8.0, 5.0/58.0	8.05, 5.2/84.2	8.0, 5.0/17.7	9.85, 8.0/11.85

¹n = 27 is the maximum number of patients included into our study.

²mean size of largest tumor in mm ± SD at time of diagnosis.

³Median AFP in ng/ml with 1^st/3^rd quartile at time of diagnosis.

⁴No statistical testing due to small sample size.

⁵No statistical testing due to high variation and SD. Patients characteristics of all patients and separated into treatment groups. Dichotomous variables are presented in number and percentage, continuous variables in mean ± SD. AFP: Alpha-fetoprotein; TACE: Transarterial chemoembolization; SBRT: Stereotactic body radiation therapy; BCLC: Barcelona clinic liver cancer.